pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
NovaPharmaNews editorial coverage mentioning Amgen — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 96
- Drugs
- 124
- Patents
- 25
News & analysis
NovaPharmaNews articles mentioning Amgen — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Amgen — regulatory, clinical, and market analysis.
MariTide Phase 2 obesity data show up to 20% weight loss at one year
Amgen’s MariTide phase 2 obesity data showed up to 20% average weight loss at 52 weeks in participants without type 2 diabetes. The trial also reported up to 17% average weight loss in participants with type 2 diabetes, with placebo results provided in the published data.
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Amgen’s MariTide Phase 2 obesity study reported up to ~20% average weight loss at one year in participants without type 2 diabetes and up to ~17% in those with type 2 diabetes. The plan below focuses only on the trial facts, the placebo comparisons, and the clinical-trial readouts already supported by source material.
Amgen Inc Stock: Lung Cancer Setback Meets Steady Cash Flow
Amgen Inc faces a setback in lung cancer trials but maintains strong cash flow. This article explores its implications for investors and pharma teams.